healthcare

In a world defined by macroeconomic uncertainty and shifting geopolitical realities, Pella continues to find opportunities.

Despite growing policy uncertainty, plenty of healthcare companies have managed to put up big returns, thanks to these qualities.

The next beneficiaries of the AI boom may not just be leaders like Nvidia. Global X’s Billy Leung discusses the next wave of winners.

Despite a five-fold share price increase, this US micro cap is still a bargain.

Platinum Asset Management’s Dr Bianca Ogden and KP Rx’s Hashan de Silva share their latest investments.

Antipodes Healthcare Portfolio Manager, Nick Cameron, outlines the investment case for pharmaceutical and medical device company, Alcon AG.

Telix smashes revenue forecasts with $1.2B+ guidance, but RFK Jr. & U.S. regulatory chaos pose risks. Shane Fitzgerald remains bullish.

Despite sky-high valuations, Jun Bei Liu is bullish on Pro Medicus. She first bought at $25 - now it’s 10x’d. How much higher can it climb?

Plasma is still a winner for the healthcare giant, but vaccinations face hurdles.

This commercial med-tech is valued at just ~A$40m despite having innovative tech, market adoption and a partnership with a global giant.